Private financing raises $26 million for Nanogen:
This article was originally published in Clinica
Nanogen has netted $26 million in a private round of financing managed by brokers Cowen & Co. Nanogen's R&D is centred on its Automated Programmable Electronic Matrix (APEX) microchip technology. Based in San Diego, California, the company is working on products for infectious disease diagnosis and genetic screening among others.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.